KPV peptide
Also known as Lys-Pro-Val, alpha-MSH 11-13, KPV tripeptide
KPV peptide is a three-amino-acid fragment of alpha-MSH studied in mice and cell cultures for gut and skin inflammation. No human trial has been published, and it is not FDA-approved.
Evidence grade D · 8 citations · Last reviewed October 2026
- Regulatory status
- Not FDA-approved. The draft, non-binding HHS policy of October 28, 2026 extends enforcement discretion to 503A-compounded KPV acetate in topical and oral forms only (no injection), subject to ten stated conditions, one of which is documented oral bioavailability for oral products. That is not approval.
- Common routes
- Topical · oral (the only routes the HHS policy covers)
KPV: the quick answer
- What is KPV?
- A three-amino-acid fragment (lysine-proline-valine) of the hormone alpha-MSH, sold for gut and skin inflammation.
- How strong is the evidence?
- Cell and mouse studies only. No human trial of KPV for any condition has been published.
- US status (as of October 2026)
- Not FDA-approved. Under a draft, non-binding policy, HHS says it does not intend to bring enforcement action against 503A compounding of KPV acetate when ten conditions are met, for topical and oral products only. Injectable KPV and research-chemical vials are outside the policy.
Overview
KPV is a tripeptide, three amino acids long (lysine, proline, valine). Those three residues form the tail end (the C-terminus) of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with known anti-inflammatory effects, and a 2007 review attributed most of alpha-MSH's anti-inflammatory activity to this C-terminal fragment [2]. Unlike full-length alpha-MSH, KPV is not marketed for tanning or appetite; it is sold for gut and skin inflammation.
All of the published evidence for KPV comes from cell cultures and mice. We searched PubMed for a human clinical trial of KPV and found none. In a draft enforcement policy dated October 28, 2026, HHS says it does not intend to bring enforcement action against licensed 503A pharmacies and physicians that compound KPV, but only in topical and oral forms and only when ten conditions are met [1]. That makes a prescribed, pharmacy-made KPV possible in the US. It does not add any human evidence that KPV works.
Regulatory status
FDA has approved KPV for nothing. The October 28, 2026 HHS document is an interim, draft enforcement-discretion policy that is neither final nor binding on HHS or the public, and comments are open until November 13, 2026. Whether KPV ends up on the 503A bulk drug substances list is a question FDA will settle through rulemaking. Until then, HHS says that when every one of ten conditions is met, it does not intend to bring enforcement action against anyone compounding KPV acetate, whether a State-licensed pharmacy, a licensed physician, or a Federal facility [1]. The policy also states plainly that compounded drugs are unapproved and that FDA does not look at their safety, effectiveness, or quality.
Route limits: the policy covers KPV acetate in topical and oral dosage forms only [1]. Injectable KPV is outside it, and the three routes are compared in KPV capsules, cream or injection. Oral peptide products carry an extra burden: the compounder needs records showing that its particular formulation is adequately bioavailable by mouth in humans [1].
The rest of the list: each product is prescribed for a specific patient and holds KPV as its sole active ingredient (blends do not qualify). The bulk KPV is made by an FDA-registered manufacturer and travels with a certificate of analysis showing identity, purity and potency plus results for endotoxin, heavy metals, microbial limits and impurities. Serious adverse events and quality defects are reported to the states and FDA MedWatch, and one condition is that the label carries the sentence "This is a compounded drug product. Not for resale." Should safety or quality problems show up, HHS can reopen the policy [1].
History: from September 2023 to April 22, 2026, both KPV (free base) and KPV acetate were in FDA's Category 2. FDA's drug center (CDER) recommended against listing it, and the Pharmacy Compounding Advisory Committee voted in favor [1]. HHS's stated reasons for including it were documented use, an improved quality record for the acetate form, and its view that CDER's safety conclusion reflected missing information rather than an observed harm [1]. An independent analysis of the advisory committee review is available in the compounding trade literature [7].
Where to get KPV
Every telehealth provider we track that offers KPV. Partners we work with are shown first.
Editorial score · methodology
Pepti
Best for: a low all-in starter price on compounded GLP-1s, with every dose price published up front
Editorial score · methodology
OurView Health
Best for: low, flat compounded GLP-1 pricing at any dose, with no membership fee
Editorial score · methodology
Editorial score · methodology
HuHealth
Best for: choosing your compounding pharmacy, or brand Zepbound and Wegovy at the maker's price plus a $59 care plan
Editorial score · methodology
Enhanced
Best for: prepaying for low-cost compounded GLP-1s with peptides available from one brand
Editorial score · methodology
RxPepsDirect
Best for: Lowest per-vial GLP-1 cost: sema $25, tirz $45, $39 telehealth Rx, 28 states
Editorial score · methodology
Scripts Rx Direct
Best for: compounded peptides priced up front, including KPV, MOTS-c, epitalon and semax nasal spray
Editorial score · methodology
Rehydra+ Wellness
Best for: dose-by-dose price transparency and phone or text support, if it ships to your state
Editorial score · methodology
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
What does KPV do? Claims vs evidence
Each row is a claim as it is commonly marketed, the strongest kind of evidence behind it, and what that evidence found. Numbers in brackets point to the sources at the end of this page.
| Claim | Evidence | What the studies found | Sources |
|---|---|---|---|
| Calms gut inflammation (colitis, IBD) | Animal studies | In mouse colitis models from two research groups, KPV reduced inflammation and inflammatory cytokines and sped recovery and weight regain. No human trial in inflammatory bowel disease has been published. | Sources:[3][4] |
| Works when taken by mouth | Animal studies | Cell studies show the gut's PepT1 transporter carries KPV into cells, and KPV given in drinking water or in oral nanoparticles worked in mice. Oral absorption in people has not been measured. | Sources:[3][5] |
| Blocks inflammation inside cells | Cell studies only | In human intestinal and immune cell lines, nanomolar KPV blocked NF-kappaB and MAP kinase signaling and reduced inflammatory cytokine release. | Sources:[3] |
| Soothes skin inflammation | Animal studies | Alpha-MSH, the hormone KPV comes from, reduced inflammation in animal models of contact dermatitis and other conditions, and a review credits most of that activity to KPV. No study has tested a topical KPV product in people. | Sources:[2] |
| Safe for everyday use | No direct evidence | No human safety data exist. FDA's earlier review recorded no human exposure by any route, and HHS describes CDER's safety concern as missing data rather than an observed harm. | Sources:[1] |
Evidence levels, strongest first: FDA-approved use, human studies (of any size or design), animal studies, cell studies only, and no direct evidence (nothing tests the claim for this compound).
How it works
In human intestinal and immune cell lines, nanomolar concentrations of KPV blocked activation of NF-kappaB and MAP kinase signaling and reduced inflammatory cytokine release. The same study found that KPV enters cells through PepT1, a carrier for small dietary peptides that lives mainly in the small intestine but becomes active in an inflamed colon [3]. That transporter is the main reason KPV is discussed as an oral peptide, which is unusual: most peptides are broken down in the gut.
Alpha-MSH acts largely through the melanocortin-1 receptor. KPV's effect in one mouse study persisted in animals with a non-functional version of that receptor, which suggests KPV works at least partly through a different route [4]. Reviews of the melanocortin system in inflammatory bowel disease treat KPV as one of several candidate molecules, with the supporting data drawn from mouse colitis models [6].
What the evidence says
The gut evidence is entirely in mice. In two chemically induced colitis models, KPV added to drinking water reduced colitis and inflammatory cytokine expression [3]. A second group tested KPV in two colitis models and reported earlier recovery, stronger regain of body weight, less inflammatory infiltrate, and lower myeloperoxidase activity; in mice lacking a working melanocortin-1 receptor, KPV treatment kept every treated animal alive through DSS colitis [4]. A later study packaged KPV in hyaluronic-acid nanoparticles and found the oral nanoparticle form protected the colon lining better than a comparison KPV formulation in a mouse ulcerative colitis model [5]. Each of these colitis studies is walked through in our KPV gut inflammation review.
The skin and topical case is even thinner. The anti-inflammatory effects of alpha-MSH have been shown in animal models of contact dermatitis, vasculitis, asthma, colitis and arthritis, and that review credits most of the activity to the KPV fragment [2], but we found no published study of a topical KPV product in people.
Evidence grade: D. There is no human trial of KPV for inflammatory bowel disease, leaky gut, skin conditions, or anything else. The mouse results are consistent and come from more than one group, which is better than many research peptides manage, but mouse colitis is a model, and the history of inflammatory bowel disease drugs includes many compounds that worked in mice and failed in people.
Typical dosing
There is no established human dose of KPV by any route, because no human study has been published. The mouse studies gave KPV in drinking water or in nanoparticles, and those amounts do not translate to a human dose. We do not publish a protocol. If a clinician prescribes compounded KPV under the HHS policy, the product will be topical or oral, and the strength and schedule are the prescriber's decision, not something an evidence base supports.
Safety & side effects
Human safety data for KPV do not exist in the published literature. FDA's earlier review recorded no human exposure data by any route, and HHS, explaining why it included KPV, characterizes CDER's concern as missing data, not a harm anyone saw [1]. Both statements mean the same thing for a patient: nobody knows the side-effect profile.
The practical risk differs by source. Research-chemical KPV sold online "for research use only" has no verified identity, purity, or sterility. A KPV product compounded under the HHS policy must come from a registered manufacturer with a lot-level certificate of analysis, contain KPV alone, and be reported to MedWatch if a serious adverse event occurs [1]. That is a real quality difference. It is not evidence of effectiveness.
Frequently asked questions
Is KPV FDA-approved?
No. KPV has no FDA approval for any use. In a draft policy from October 28, 2026, HHS says it does not intend to bring enforcement action against 503A pharmacies and physicians that compound KPV acetate as a topical or oral product under ten conditions. That is enforcement discretion while FDA decides on the 503A bulks list, not approval.
What does KPV do?
Is KPV safe?
Its safety in people is unknown. No human safety data for KPV have been published, and FDA's earlier review recorded no human exposure by any route [1], so there is no documented side-effect profile, good or bad. A product compounded under the HHS policy has a lot-level certificate of analysis for identity and purity; research-chemical KPV does not.
Can KPV be injected under the new policy?
No. The HHS policy covers KPV acetate in topical and oral dosage forms only. An injectable KPV product falls outside the policy.
Does KPV work for leaky gut or IBD?
Nobody has tested it in people. In mice with chemically induced colitis, KPV reduced inflammation and helped the animals recover weight, and the effect was seen by more than one research group. No human trial of KPV for inflammatory bowel disease, leaky gut, or any other condition has been published.
Why is KPV taken orally when most peptides are injected?
Cell studies show KPV is carried into intestinal cells by PepT1, the transporter the gut uses for small dietary peptides, and mouse studies gave it in drinking water. Whether a given oral product delivers meaningful KPV in humans is unknown, which is why the HHS policy requires the compounder to document adequate oral bioavailability for oral forms.
What dose of KPV is used?
There is no established human dose, because no human study exists. Any figure quoted online is not derived from human data. If a clinician prescribes it, the dose is their clinical judgment.
How is KPV different from BPC-157?
Both are on the HHS Appendix A list and both are discussed for gut inflammation, but they are unrelated molecules. KPV is a three-amino-acid fragment of alpha-MSH; BPC-157 is a 15-amino-acid fragment of a gastric protein. The routes differ too: the policy allows BPC-157 by injection, orally and topically, and KPV only orally and topically. Neither has a completed human trial.
Is KPV banned in sports?
KPV is not named on WADA's 2026 Prohibited List. Its S0 class prohibits at all times any pharmacological substance not covered elsewhere on the List and not approved by any governmental health authority for human therapeutic use, so an athlete subject to anti-doping rules should check with their anti-doping organization before using it.
Sources
- [1] US Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A: list; Appendix B: identities, routes, and justifications). HHS (2026). Source
- [2] Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis (2007). PMID 17934097
- [3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). PMID 18061177
- [4] Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis (2008). PMID 18092346
- [5] Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther (2017). PMID 28143741
- [6] Gravina AG, Pellegrino R, Durante T, Palladino G, Imperio G, D'Amico G, et al. The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Cells (2023). PMID 37508552
- [7] Willis J, Vu N. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Int J Pharm Compd (2026). PMID 42752426
- [8] World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances). WADA (2026). Source
Further reading
- KPV and gut inflammation: the full evidence review Every mouse and cell study, study by study.
- KPV providers Every clinic we confirmed sells single-ingredient KPV, with the form each one sells. A listing does not confirm the pharmacy meets the policy's conditions.
- How the HHS 503A peptide policy works What the October 2026 policy allows, its ten conditions, and what it leaves out.
- News: HHS enforcement discretion for six compounded peptides Our report on the October 28, 2026 announcement.
- KPV by route Capsules, cream or injection, and which forms the policy covers.
- The KLOW peptide blend Injected KPV in a four-peptide blend, outside the topical and oral routes.
- BPC-157 The other Appendix A peptide sold for gut repair, with a much larger animal literature.
- BPC-157 for gut health and leaky gut How the two gut-repair peptides compare on evidence.
- Are peptides legal? Research chemicals versus prescribed, compounded peptides.
- All peptides we cover Evidence grades and regulatory status side by side.
Related peptides
Browse the full peptide directory, see what GLP-1s treat by condition, or compare the best GLP-1 providers.
Educational information only — not medical advice.